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ABSTRACT
Background: Polymorphisms which are presented below may be the cause of inherited thrombophilia and may result 
in pregnancy loss. The hypothesis is based on a number of cardiology studies which have confirmed the involvement of 
these polymorphisms in thrombotic incidents.
Objectives: To evaluate the role of polymorphisms of factor VII gene (Arg353Gln, -122T > C) and PAI-1 gene (-675 4G/5G) in 
the etiology of recurrent miscarriage.
Material and methods: The study group included 152 women with a positive history of ≥ 2 consecutive pregnancy losses 
(114 and 38 women with 2 and ≥ 3 miscarriages, respectively), while 180 healthy women were recruited as controls. Genetic 
analysis was performed with the use of PCR/RFLP.
Results: Lower frequency of Arg353/Gln353 was observed in women with 2 and ≥ 3 miscarriages as compared to controls 
(21.1% vs. 23.9% and 13.2% vs. 23.9%, respectively). The frequency of Gln353 was lower in women with ≥ 3 miscarriages 
as compared to controls (6.6% vs. 11.9%, p = ns). The frequency of -122TT was higher in women with ≥ 3 miscarriages 
as compared to controls (86.84% vs. 76.67%, p = ns), whereas -122TC was more frequent in controls (13.16% vs. 22.78% 
in controls, p = ns). The frequency of -122T was higher in patients with ≥ 3 abortions as compared to controls (93.42% 
vs. 88.06%, p = ns), and -122C was observed more frequently in controls (6.58% vs. 11.94% in controls, p = ns). There were 
no significant differences as far as the -675 4G/5G polymorphism was concerned.
Conclusions: The obtained results suggest a possible protective role of Gln353 and -122C alleles in recurrent miscarriage.
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INTRODUCTION
The etiology of recurrent miscarriage may be identified 
in only about 30–50% of the affected patients. Importantly, 
numerous studies have already proven the existence of 
a correlation between inherited thrombophilia and preg-
nancy loss [1–6]. Standard diagnostic testing for throm-
bophilia in these patients involves factor V Leiden, 677C>T 
MTHFR gene polymorphism, 20210G>A prothrombin gene 
polymorphism, protein C, protein S and antithrombin de-
ficiency. However, anticoagulant treatment with heparin 
and acetylsalicylic acid is successful in the absence of the 
abovementioned genetic impairments and after exclusion 
of the antiphospholipid syndrome, suggesting the existence 
of other genetic variants, which are not included in the basic 
diagnostic algorithm, conditioning inherited thrombophilia. 
Factor VII, together with the tissue factor, takes part in 
the activation of the exogenous path of clotting and forma-
tion of a blood clot after vessel injury. Gene encoding factor 
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VII is located on the short arm of chromosome 13 and con-
tains 9 exons ((NM_000131). The majority of the identified 
factor VII gene polymorphisms are correlated with factor 
VII deficiency, resulting in exaggerated bleeding and con-
stituting a risk factor for massive hemorrhage. However, 
several polymorphisms increase factor VII activity and its 
higher concentration in serum has been described. It may 
result in an increased risk for thrombotic changes and, in 
consequence, recurrent miscarriage [7, 8].
Plasminogen activator inhibitor-1 (PAI-1) is the main 
physiological inhibitor of tissue plasminogen activator 
and urokinase plasminogen activator. It plays a vital role 
in the regulation of fibrinolytic processes and increased 
PAI-1 concentration may be the cause of thrombophilia. 
The gene encoding PAI-1 (SERPINE1) is located on the short 
arm of chromosome 7 and contains 9 exons (NM_000602). 
Genetically conditioned changes in PAI-1 serum concentra-
tion and activity may result in hypofibrinolysis, thrombotic 
changes in the utero-placental unit, and elevated risk for 
recurrent pregnancy loss. Enhanced PAI-1 secretion by 
endothelial cells leads to the formation of thrombus in the 
spiral arteries. Apart from the correlation with recurrent 
miscarriage, PAI-1 gene polymorphisms may be connected 
with the development of preeclampsia, gestational hyper-
tension, intrauterine growth restriction, or intrauterine 
fetal death [9, 10].
The aim of our research was to investigate the possibil-
ity of a correlation between selected genetic variants of 
factor VII (Arg353Gln and -122T>C) and PAI-1 (-675 4G/5G) 
and recurrent miscarriage. Polymorphisms which have 
been presented below may be the cause of inherited 
thrombophilia and may result in pregnancy loss. The hy-
pothesis is based on a number of cardiology studies which 
have confirmed the involvement of these polymorphisms 
in thrombotic incidents [11–18].
MATERIAL AND METHODS
All participants (Polish origin, Caucasian race) were 
recruited at the Department of Perinatology and Wom-
en’s Diseases, Poznan University of Medical Sciences, 
between 2011–2013. A total of 152 women (mean age 
30.16 ± 3.82 years, range 21–45 years, median 30 years) with 
a history of ≥ 2 consecutive miscarriages were enrolled into 
the study. Spontaneous abortion was defined as the loss of 
pregnancy before 22 completed weeks of gestation. Patients 
with known causes of recurrent miscarriage (anatomical 
anomalies of the genitourinary tract, chromosomal defect, 
chronic disease, infection, hormonal impairment, antiphos-
pholipid antibodies, thromboembolic disease, cervical insuf-
ficiency or other obstetric complications which could cause 
miscarriage, e.g. hypertension, preeclampsia, eclampsia, 
gestational diabetes mellitus) were excluded. The study 
group was subdivided based on the number of spontaneous 
abortions: 114 with 2 and 38 women with ≥ 3 consecutive 
miscarriages.
The control group included 180 women (mean age 
29.46 ± 4.26 years, range 19–42 years, median 29 years) 
with a positive history of ≥ 1 uncomplicated pregnancy 
(healthy term newborn). All women with a history of miscar-
riage, other obstetric complications which might be related 
to thrombotic changes (preeclampsia, fetal hypotrophy, 
preterm delivery, preterm placental ablation, intrauterine 
fetal death), thromboembolic disease, and chronic diseases 
were excluded.
Genotyping of Arg353Gln and -122T>C factor VII gene 
polymorphisms and -675 4G/5G PAI-1 gene polymorphism 
was performed for the entire study population. Genetic 
analysis was performed with the use of polymerase chain 
reaction/restriction fragments length polymorphism meth-
od (PCR/RFLP). Genomic DNA was extracted from blood 
leucocytes using QIAamp DNA Blood Mini Kit (QIAGEN Inc., 
Germany). Starters used for amplification and restriction 
enzymes used to obtain better resolution for visualization 
are shown in Table 1. The analysis of the digested fragments 
was performed using 2% agarose gel electrophoresis.
Statistical analysis was performed using SPSS 22.0 PL 
for Windows. Frequencies of genotypes were compared 
with chi-square test (one-sided Fisher test). The expected 
Table 1 Starters and restriction enzymes used in genetic analysis
Starters Restriction enzyme
Recognized 
sequence Digested fragments
Arg353Gln F 5’-GGG AGA CTC CCC AAA TAT CAC-3’R 5’-ACG CAG CCT TGG CTT TCT CTC-3’
MspI
(EURx) C^CGG
Arg353/Arg353 – 206, 67, 39 bp
Arg353/Gln353 – 273, 206, 67, 39 bp
Gln353/Gln353 – 273, 39 bp
-122T>C F 5’-TCG CAT GAT TGC TAT GGG AC-3’R 5’-GTT GAC ATT CCC CAT GGG AC– 3’
SduI (Bsp1286I)
(Thermo Scientific) GDGCH^C
-122TT – 200 (210),156 bp
-122TC – 200 (210),156, 90, 66 bp
-122CC – 200 (210), 90, 66 bp
-675 4G/5G 5’-GCC CTC AGG GGC ACA GAG AGA GTC TGG CCA-3’5’-GCA ATG CAG CCA GCC ACG TG — 3’
BsII
(Thermo Scientific) CCNNNNN^NNGG
-675 4G 107, 56 bp
-675 5G 74, 56, 34 bp
506
Ginekologia Polska 2016, vol. 87, no. 7
www. journals.viamedica.pl/ginekologia_polska
genotype frequencies were calculated from allele frequen-
cies with the Hardy-Weinberg equation.
All patients gave their written confirmed consent for 
the study. Local Ethics Committee approved of the study 
(no. 422/11).
RESULTS
Arg353Gln factor VII gene polymorphism
The frequency of the Arg353/Arg353 genotype was slight-
ly higher in women with 2 miscarriages (78.0% vs. 76.1% 
in controls, p = ns). The Arg353/Gln353 genotype was ob-
served more frequently in controls as compared to women 
with 2 pregnancy losses (21.1% vs. 23.9% in controls, p = ns). 
The mutated Gln353/Gln353 genotype was present only in 
1patient from that subgroup and in none of the controls 
(0.9% vs. 0.0% in controls, p = ns). There were no statistically 
significant differences in the frequency of alleles between 
both analyzed groups (Arg353: 88.6% vs. 88.1% in controls, 
p = ns; Gln353: 11.4% vs. 11.9% in controls, p = ns) (Table 2).
The differences between genotype and allele frequen-
cies were more clear between the group with ≥ 3 miscarriag-
es and controls. The homozygotic Arg353/Arg353 genotype 
was slightly more frequent in the group with ≥ 3 miscarriag-
es (86.8% vs. 76.1% in controls, p = ns). The study revealed 
an overrepresentation of heterozygotic Arg353/Gln353 geno- 
type in controls (23.9% in controls vs. 13.2%, p = ns). The 
frequency of the Arg353 allele was slightly higher in the 
group with ≥ 3 spontaneous abortions (93.4% vs. 88.1% in 
controls, p = ns) and the mutated Gln353 allele was more fre-
quent in controls (11.9% in controls vs. 6.6%, p = ns) (Table 2).
-122T>C factor VII gene polymorphism
The frequency of genotypes and alleles of the -122T>C 
polymorphism was similar in the group with 2 miscarriages 
and in controls (-122TT: 78.07% vs. 76.67% in controls, p = ns; 
-122TC: 20.18% vs. 22.78% in controls, p = ns; -122CC: 1.75% 
vs. 0.55% in controls, p = ns; -122T: 88.16% vs. 88.06% in 
controls, p = ns; -122C: 11.84% vs. 11.94% in controls, p = ns) 
(Table 3). 
Slightly higher frequency of the homozygotic -122TT 
genotype was observed in the group with ≥ 3 pregnancy 
losses (86.84% vs. 76.67% in controls, p = ns), and the het-
erozygotic -122TC genotype was found more frequently 
in controls than in women with ≥ 3 miscarriages (13.16% 
vs. 22.78% in controls, p = ns). -122T allele was more frequent 
in the study group of women with 3 or more miscarriages 
(93.42% vs. 88.06% in controls, p = ns) and the mutated 
-122C allele — in controls (6.58% vs. 11.94% in controls, 
p = ns) (Table 3).
-675 4G/5G PAI-1 gene polymorphism
The frequency of genotypes and alleles was compa-
rable in the group with 2 miscarriages and in controls 
(-675 4G/-675 4G: 32.5% vs. 35.0%, p = ns; -675 4G/-675 5G: 
49.1% vs. 47.%, p = ns; -675 5G/-675 5G: 18.4% vs. 17.8%, 
p = ns; allele -675 4G: 57.0% vs. 58.6%, p = ns; -675 5G: 43.0% 
vs. 41.4%, p = ns) (Table 4). Similar observation was made 
for the group with ≥ 3 pregnancy losses (-675 4G/-675 4G: 
34.2% vs. 35.0%, p = ns; -675 4G/-675 5G: 50.0% vs. 47.2%, 
p = ns; -675 5G/-675 5G: 15.8% vs. 17.8%, p = ns; allele 
-675 4G: 59.2% vs. 58.6%, p = ns; -675 5G: 40.8% vs. 41.4%, 
p = ns) (Table 4).
Table 2. The frequency of genotypes and alleles of the Arg353Gln factor VII gene polymorphism in the groups with a history of 2 and ≥ 3 miscarriages
Arg353Gln
Study group
(n = 152) Control group
(n = 180)2 miscarriages
(n = 114)
≥ 3 miscarriages
(n = 38)
Genotypes
Observed 
value
n [%]
Expected 
value
[%]
OR P
Observed 
value
n [%]
Expected 
value
[%]
OR P
Observed 
value
n [%]
Expected 
value
 [%]
Arg353/Arg353 89 (78.0) 78.5 1.12 0.40 33 (86.8) 87.2 2.07 0.10 137 (76.1) 77.5
Agr353/Gln353 24 (21.1) 20.2 0.85 0.34 5 (13.2) 12.3 0.48 0.10 43 (23.9) 21.1
Gln353/Gln353 1 (0.9) 1.3 – 0.39 0 (0.00) 0.5 – 1 0 (0.0) 1.4
Total 114 (100.0) 100 38 (100.0) 100.0 180 (100.0) 100
Alleles
Arg353 202 (88.6) - 1.05 0.48 71 (93.4) - 1.93 0.12 317 (88.1) –
Gln353 26 (11.4) - 0.95 0.48 5 (6.6) - 0.52 0.12 43 (11.9) –
Total 228 (100.0) - 76 (100.0) - 360 (100.0) –
Analyzed subgroups were compared to the control group
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DISCUSSION
Arg353Gln factor VII gene polymorphism
To the best of our knowledge, there has been only one 
report on the correlation of the Arg353Gln factor VII gene 
polymorphism and the risk of recurrent miscarriage, i.e. the 
study by Seremak-Mrozikiewicz et al. [7], so far. Our study 
has been the second analysis on the correlation between the 
Arg353Gln factor VII gene polymorphism and recurrent preg-
nancy loss. Seremak-Mrozikiewicz et al., based their research 
hypothesis on a number of cardiology reports, suggesting 
the existence of a correlation between the abovementioned 
genetic variant and elevated risk for cardiovascular disease. 
It is believed that the presence of the mutated Gln353 al-
lele leads to decreased concentration and activity of factor 
VII, resulting in lower intensity of coagulation cascade and 
reduced risk for thrombotic changes [7, 19].
In the cited paper (by Seremak-Mrozikiewicz), the study 
group included 104 patients with ≥ 2 miscarriages between 
6–13 weeks of gestation and 163 healthy controls with 
a negative history of pregnancy loss and a positive his-
tory of ≥ 1 uncomplicated pregnancy (healthy newborn at 
term). Their study revealed a slightly higher frequency of 
the Arg353/Arg353 genotype in the study group (89.69% 
Table 3. The frequency of genotypes and alleles of the -122T>C factor VII gene polymorphism in the groups with a history of 2 and ≥ 3 miscarriages
-122T>C
Study group
(n = 152) Control group
(n = 180)2 miscarriages
(n = 114)
≥ 3 miscarriages
(n = 38)
Genotypes
Observed 
value
n [%]
Expected 
value 
[%]
OR P
Observed 
value
n [%]
Expected 
value 
[%]
OR P
Observed 
value
n [%]
Expected 
value 
[%]
TT 89 (78.07) 77.72 1.08 0.45 33 (86.84) 87.27 2.01 0.12 138 (76.67 ) 77.54
TC 23 (20.18) 20.88 0.86 0.35 5 (13.16) 12.29 0.51 0.13 41 ( 22.78) 21.03
CC 2 (1.75) 1.40 3.20 0.33 0 (0.00) 0.43 ─ 0.83 1 ( 0.55) 1.43
Total 114 (100.0) 100.0 38 (100.0) 100.0 180 (100.00) 100
Alleles
T 201 (88.16) – 1.01 0.54 71 (93.42) – 1.93 0.12 317 (88.06) –
C 27 (11.84) – 0.99 0.54 5 (6.58) – 0.52 0.12 43 (11.94) –
Total 228 (100.0) – 76 (100.0) – 360 (100.0) –
Analyzed subgroups were compared to the control group
Table 4. The frequency of genotypes and alleles of the -6754G/-675 5G PAI-1 gene polymorphism in in the groups with a history of 
2 and ≥ 3 miscarriages
-675 4G/5G
Study group
(n = 152) Control group
(n = 180)2 miscarriages
(n = 114)
≥ 3 miscarriages
(n = 38)
Genotypes
Observed 
value
n [%]
Expected 
value 
[%]
OR P
Observed 
value
n [%]
Expected 
value 
[%]
OR P
Observed 
value
n [%]
Expected 
value 
[%]
4G/4G 37 (32.5) 32.5 0.89 0.37 13 (34.2) 35.0 0.97 0.54 63 (35.0) 34.4
4G/5G 56 (49.1) 49.0 1.08 0.42 19 (50.0) 48.3 1.12 0.45 85 (47.2) 48.5
5G/5G 21 (18.4) 18.5 1.04 0.50 6 (15.8) 16.7 0.87 0.49 32 (17.8) 17.1
Total 114 (100.00) 114 (100.0) 38 (100.0) 38 (100.0) 180 (100.0) 100
Alleles
4G 130 (57.0) – 0.94 0.38 45 (59.2) – 1.03 0.51 211 (58.6) –
5G 98 (43.0) – 1.07 0.38 31 (40.8) – 0.98 0.51 149 (41.4) –
Total 228 (100.0) – 76 (100.0) – 360 (100.0) –
Analyzed subgroups were compared to the control group
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vs. 74.5% in controls, p = 0.086). Moreover, overrepresenta-
tion of the Arg353/Gln353 genotype was observed in controls 
(17.31% vs. 25.15% in control group, p = 0.086). The frequen-
cy of the mutated Gln353 allele was also higher in controls 
(12.58% in controls vs. 8.65%, p = 0.101). Further analysis 
revealed a lower frequency of the Arg353/Gln353 genotype 
in the group with 2 miscarriages, as well as w ≥ 3 miscar-
riages as compared to controls (respectively, 16.25% and 
20.83% vs. 25.15%) [7].
The obtained results suggest a possible protective role 
of the mutated Gln353 allele of the Arg353Gln factor VII gene 
polymorphism in recurrent miscarriage. Similar conclusions 
were reported by Seremak-Mrozikiewicz et al.
-122T>C factor VII gene polymorphism
To the best of our knowledge, the literature offers no 
reports on the correlation between -122T>C factor VII gene 
polymorphism and recurrent miscarriage and our study 
has been the first on the topic in question. It points out 
a possible protective role of the mutated -122C allele of the 
-122T>C factor VII gene polymorphism in the occurrence of 
recurrent abortions, especially in women with ≥ 3 pregnancy 
losses. It is indicated by a slightly higher frequency of the 
-122TT genotype in the group with ≥ 3 miscarriages (86.84% 
vs. 76.67% in controls, p = 0.12) and overrepresentation of 
the -122TC genotype in controls (13.16% vs. 22.78% in con-
trols, p = 0.13). Moreover, the frequency of the -122T allele 
was higher in the group with ≥ 3 pregnancy losses (93.42% 
vs. 88.6% in controls, p = 0.12) and the mutated -122C allele 
was noted more frequently in controls (6.58% vs. 11.94% in 
controls, p = 0.12).
-675 4G/5G PAI-1 gene polymorphism
The abovementioned polymorphism is one of the most 
often studied PAI-1 functional genetic variants as far as its 
correlation with obstetric complications is concerned. The 
-675 4G allele determines increased PAI-1 concentration and 
enhanced prothrombotic activity. The -675 4G/5G polymor-
phism has been suggested to be involved in the etiology 
of intrauterine fetal death, intrauterine growth restriction, 
preterm placental abruption, recurrent miscarriage, and 
preeclampsia [20, 21].
Increased PAI-1 concentration and reduction of fibrinoly-
sis is observed in carriers of the homozygotic -675 4G/-675 4G 
genotype as compared to carriers of the -675 5G/-675 5G 
genotype. Intermediate value of the PAI-1 concentration 
is noted in carriers of the heterozygotic -675 4G/-675 5G 
genotype. So, it is believed that the mutated -675 5G allele 
may play a protective role in recurrent pregnancy loss. In 
our study, no significant differences between the analyzed 
groups were observed. The conducted analysis did not re-
veal any correlation of the -675 4G/5G PAI-1 gene polymor-
phisms with the risk of recurrent miscarriage. However, nu-
merous contemporary studies have confirmed the influence 
of the abovementioned genetic variant on elevated risk for 
recurrent pregnancy loss.
The aim of the research by Subrt et al., was to evaluate 
the frequency of genotypes and alleles of the -675 4G/-
675 5G PAI-1 gene polymorphism and its correlation with 
the presence of antiphospholipid antibodies in a group of 
157 women with a positive history of recurrent spontane-
ous abortion. The study revealed a statistically significant 
connection between this obstetric complication and the 
-675 4G/-675 4G genotype. Regardless, no correlation with 
the presence of antiphospholipid antibodies was found [22].
The study by Ivanov et al., also suggests an independent 
role of the -675 4G/-675 5G PAI-1 gene polymorphism in the 
etiology of recurrent pregnancy loss. Their study population 
included 110 women with a history of recurrent miscar-
riage and 97 healthy controls. These authors evaluated the 
frequency of the -675 4G/-675 5G PAI-1 gene polymorphism, 
20210G>A prothrombin gene polymorphism, 677C>T MTHFR 
gene polymorphism and factor V Leiden. Higher frequency 
of the -675 4G/-675 5G PAI-1 gene polymorphism was noted 
in the study group (41.8% vs. 26.8%, WR 1.96; p = 0.034). 
Moreover, this difference remained significant even after 
the exclusion of the carriers of the 20210G>A prothrombin 
gene polymorphism, 677C>T MTHFR gene polymorphism 
and factor V Leiden from the analysis [23].
Coulam et al., conducted a very interesting analysis on 
genetically conditioned thrombophilia and its correlation 
with recurrent pregnancy loss. These authors based their hy-
pothesis on the well-documented fact that inherited throm-
bophilia constitutes a risk factor for cardio-vascular diseases 
and obstetric complications. The aim of their study was to 
compare the frequency of nine mutations correlated with 
thrombophilia in a group of 550 women with a history of 
recurrent miscarriage, in 43 patients with deep vein throm-
bosis, and in 41 healthy controls. Each patient was geno-
typed for the presence of the 1691G>A and H1299R factor V 
gene polymorphism, 20210G>A prothrombin gene polymor-
phism, V34L factor XIII gene polymorphism, -455G>A beta-fi-
brinogen gene polymorphism, 677C>T and 1298A>C MTHFR 
gene polymorphism, and -675 4G/5G PAI-1 gene polymor-
phism. The frequency of all genetic variants was higher in 
patients with deep vein thrombosis as compared to controls 
and women with recurrent miscarriage. The V34L factor XIII 
gene polymorphism and -675 4G/5G PAI-1 gene polymor-
phism were statistically more often observed in the group 
with pregnancy loss as compared to controls. These authors 
concluded that basic testing for thrombophilia should also 
include the -675 4G/5G PAI-1 gene polymorphism [24].
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CONCLUSIONS
1. The obtained results suggest a possible protective role 
of the mutated Gln353 allele of the Arg353Gln factor VII 
gene polymorphism in recurrent miscarriage.
2. The present study points out a possible protective role 
of the mutated -122C allele of the -122T>C factor VII 
gene polymorphism as far as the occurrence of recur-
rent abortion is concerned, especially in the group 
with ≥ 3 pregnancy losses.
3. The analysis did not reveal any correlations between 
-675 4G/5G PAI-1 gene polymorphisms and the risk for 
recurrent miscarriage.
4. A correlation between thrombophilia and recurrent mis-
carriage has been observed by numerous authors. How-
ever, the pathological mechanisms involved in the pro-
cess remain poorly understood. The etiology of recurrent 
pregnancy loss is multifactorial and efficient treatment 
remains a challenge. Further studies are essential in 
order to obtain strong evidence.
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